FDAapproval83% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Regeneron.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Skin Cancer
- Sub-indication
- General
Related signal: Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer
Source
FDA document
View source